Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8018454,EC50,"Using the sigmoidal Emax model the mean serum concentration of azapropazone inhibiting platelet TXB2 generation by 50% (EC50) was found to be 98.1 +/- 41.9 (s.d.) micrograms ml-1, a value 1000 times higher than that for rac-ketorolac.",Effects on platelet functions and pharmacokinetics of azapropazone and ketorolac tromethamine given as single parenteral doses. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018454/),[μg] / [ml],98.1,5123,DB00500,Tolmetin
,1261159,T1/2,"Tolmetin, a nonsteroidal anti-inflammatory drug, is rapidly absorbed (10 to 20 min) and rapidly excreted (T1/2 congruent to 60 min) and shows a linear dose-plasma level response in the therapeutic dose range.",Absorption and excretion of tolemetin in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261159/),min,60,6105,DB00500,Tolmetin
,3264245,terminal half-life,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),h,5.09,8082,DB00500,Tolmetin
,3264245,plasma clearance (CL,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[ml] / [kg·min],0.35,8083,DB00500,Tolmetin
,3264245,tissue distribution (Vss,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[l] / [kg],0.11,8084,DB00500,Tolmetin
,3264245,V beta,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[l] / [kg],0.17,8085,DB00500,Tolmetin
,3264245,peak levels,"Following i.m. and p.o. administration, peak levels of approximately 0.8 microgram/ml were rapidly attained (tmax = 0.8 and 0.9 h, respectively) and the systemic bioavailability was essentially complete.","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[μg] / [ml],0.8,8086,DB00500,Tolmetin
,3264245,tmax,"Following i.m. and p.o. administration, peak levels of approximately 0.8 microgram/ml were rapidly attained (tmax = 0.8 and 0.9 h, respectively) and the systemic bioavailability was essentially complete.","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),h,0.8,8087,DB00500,Tolmetin
,3264245,tmax,"Following i.m. and p.o. administration, peak levels of approximately 0.8 microgram/ml were rapidly attained (tmax = 0.8 and 0.9 h, respectively) and the systemic bioavailability was essentially complete.","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),h,0.9,8088,DB00500,Tolmetin
,2717521,AUC ratios,"The amount of PHK circulating in plasma was very low as judged by AUC ratios (PHK/K x 100) of 1.9 and 1.5% for the 30-mg po and im doses, respectively.",Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717521/),%,1.9,9597,DB00500,Tolmetin
,2717521,AUC ratios,"The amount of PHK circulating in plasma was very low as judged by AUC ratios (PHK/K x 100) of 1.9 and 1.5% for the 30-mg po and im doses, respectively.",Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717521/),%,1.5,9598,DB00500,Tolmetin
,2717521,plasma half-life,"The mean plasma half-life of K was remarkably consistent between po and im administration and was independent of dose, ranging from 5.21 to 5.56 hr.",Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717521/),h,5.21 to 5.56,9599,DB00500,Tolmetin
,8801333,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 0.20, 0.18, and 0.82 microgram/mL for TD-A, TD-B, and TD-C, respectively.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),[μg] / [ml],0.20,17443,DB00500,Tolmetin
,8801333,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 0.20, 0.18, and 0.82 microgram/mL for TD-A, TD-B, and TD-C, respectively.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),[μg] / [ml],0.18,17444,DB00500,Tolmetin
,8801333,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 0.20, 0.18, and 0.82 microgram/mL for TD-A, TD-B, and TD-C, respectively.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),[μg] / [ml],0.82,17445,DB00500,Tolmetin
,8801333,terminal half-life,"The total AUC values for the concentration-time curves were TD-C > TD-A > TD-B, and the terminal half-life ranged from 6.6 to 9.7 h.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),h,6.6 to 9.7,17446,DB00500,Tolmetin
,8148223,clearance,The mean +/- s.d. clearance of (S)-ketorolac (45.9 +/- 10.1 ml h-1 kg-1) exceeded (P = 0.0032) that of the (R)-enantiomer (19.0 +/- 5.0 ml h-1 kg-1).,The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[ml] / [h·kg],45.9,20885,DB00500,Tolmetin
,8148223,clearance,The mean +/- s.d. clearance of (S)-ketorolac (45.9 +/- 10.1 ml h-1 kg-1) exceeded (P = 0.0032) that of the (R)-enantiomer (19.0 +/- 5.0 ml h-1 kg-1).,The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[ml] / [h·kg],19.0,20886,DB00500,Tolmetin
,8148223,AUC ratio,The mean +/- s.d. AUC ratio for (S)-ketorolac:(R)-ketorolac (0.442 +/- 0.043) was significantly different from unity (P = 0.0001).,The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),,0.442,20887,DB00500,Tolmetin
,8148223,steady-state volume of distribution,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[l] / [kg],0.135,20888,DB00500,Tolmetin
,8148223,steady-state volume of distribution,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[l] / [kg],0.075,20889,DB00500,Tolmetin
,8148223,half-lives,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),h,2.35,20890,DB00500,Tolmetin
,8148223,half-lives,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),h,3.62,20891,DB00500,Tolmetin
,30303407,gel strength,"The results showed that the optimized TS-LS; composed of P407/P188/MC (21/9/0.5% w/w) displayed gelation at rectum temperature ∼32.90 °C, gel strength of 21.35 s and rectal retention force at the administration site of 24.25 × 102 dyne/cm2.",Tolmetin sodium-loaded thermosensitive mucoadhesive liquid suppositories for rectal delivery; strategy to overcome oral delivery drawbacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30303407/),s,21.35,22119,DB00500,Tolmetin
,30303407,rect,"The results showed that the optimized TS-LS; composed of P407/P188/MC (21/9/0.5% w/w) displayed gelation at rectum temperature ∼32.90 °C, gel strength of 21.35 s and rectal retention force at the administration site of 24.25 × 102 dyne/cm2.",Tolmetin sodium-loaded thermosensitive mucoadhesive liquid suppositories for rectal delivery; strategy to overcome oral delivery drawbacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30303407/),[dyne] / [cm2],24.25 ×,22120,DB00500,Tolmetin
,10205770,IC50,Population analysis yielded a maximal inhibition of the nociceptive response of 76% and an IC50 of 9.22 micrograms/ml.,Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10205770/),[μg] / [ml],9.22,28117,DB00500,Tolmetin
,10205770,IC50,This IC50 is similar to that for tolmetin-induced prostaglandin synthesis inhibition in vitro (3.0 micrograms/ml).,Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10205770/),[μg] / [ml],3.0,28118,DB00500,Tolmetin
,14570776,maximum concentration,"The initial formation rate of ZP-SG was rapid and reached a maximum concentration of 0.24 +/- 0.03 nM after 4 min of incubation, then decreased, in a fairly linear fashion, to 0.07 +/- 0.03 nM after 60 min of incubation.",Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570776/),nM,0.24,37843,DB00500,Tolmetin
,14570776,maximum concentration,"The initial formation rate of ZP-SG was rapid and reached a maximum concentration of 0.24 +/- 0.03 nM after 4 min of incubation, then decreased, in a fairly linear fashion, to 0.07 +/- 0.03 nM after 60 min of incubation.",Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570776/),nM,0.07,37844,DB00500,Tolmetin
,14570776,apparent half-life,The product ZP-SG (1 microM) was shown to be unstable by undergoing rapid hydrolysis (apparent half-life approximately 0.8 min) in incubations with rat hepatocytes.,Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570776/),min,0.8,37845,DB00500,Tolmetin
,10079499,AUC S/R,"After the racemate, R-KT was predominant in plasma (AUC S/R, 0.45).",Stereospecific pharmacokinetics and toxicodynamics of ketorolac after oral administration of the racemate and optically pure enantiomers to the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079499/),,0.45,40282,DB00500,Tolmetin
,2273487,elimination half-life,The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03).,Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),h,1.7,45863,DB00500,Tolmetin
,2273487,elimination half-life,The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03).,Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),h,1.2,45864,DB00500,Tolmetin
,2273487,apparent MTX clearance (CI),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[l] / [h],10.6,45865,DB00500,Tolmetin
,2273487,apparent MTX clearance (CI),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[l] / [h],13.1,45866,DB00500,Tolmetin
,2273487,area under the serum MTX concentration-time curve (Auc),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[μM] / [h·l],2.1,45867,DB00500,Tolmetin
,2273487,area under the serum MTX concentration-time curve (Auc),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[μM] / [h·l],1.5,45868,DB00500,Tolmetin
,2273487,apparent volume of distribution (Vd),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),l,23.0,45869,DB00500,Tolmetin
,2273487,apparent volume of distribution (Vd),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),l,21.9,45870,DB00500,Tolmetin
,30595939,gel strength,The physicochemical characterization revealed that all hydrogels had a suitable pH (6.64-7.75) and gel strength (15.5-65.29 s) for rectal application.,Pharmaceutical and pharmacokinetic evaluation of novel rectal mucoadhesive hydrogels containing tolmetin sodium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30595939/),s,15.5-65.29,46763,DB00500,Tolmetin
,30595939,relative bioavailability,Formula containing 2% CMC showed relative bioavailability 357.93%.,Pharmaceutical and pharmacokinetic evaluation of novel rectal mucoadhesive hydrogels containing tolmetin sodium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30595939/),%,357.93,46764,DB00500,Tolmetin
,8592665,AUC S/R,"In both humans and rats, the pharmacokinetics of racemic KT were stereoselective with the R enantiomer being predominant (AUC S/R: humans, 0.26; Rats: 0.45).",The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592665/),,0.26,58983,DB00500,Tolmetin
,8592665,AUC S/R,"In both humans and rats, the pharmacokinetics of racemic KT were stereoselective with the R enantiomer being predominant (AUC S/R: humans, 0.26; Rats: 0.45).",The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592665/),,0.45,58984,DB00500,Tolmetin
,8592665,unbound S/R,This is likely due to more extensive plasma protein binding of S than its antipode (unbound S/R: 1.35).,The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592665/),,1.35,58985,DB00500,Tolmetin
,8749226,half-life,"Then, concentrations decayed with a half-life of about 6 h.",Pharmacokinetics of oral ketorolac in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8749226/),h,6,60902,DB00500,Tolmetin
,3598886,ocular bioavailability,The ocular bioavailability of ketorolac was 4% in anesthetized rabbits and was determined by comparing drug concentrations in the aqueous humor after topical application with those obtained after intracameral injection of an equivalent dose of 0.25 mg of ketorolac tromethamine per eye.,Ocular bioavailability and tissue distribution of [14C]ketorolac tromethamine in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598886/),%,4,75893,DB00500,Tolmetin
,3874742,bioavailability,"Probenecid decreased total plasma clearance of zomepirac by 64%, which resulted in an increase in bioavailability from 0.55 without probenecid to 0.84 when given concurrently.",Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3874742/),,0.55,81793,DB00500,Tolmetin
,3874742,bioavailability,"Probenecid decreased total plasma clearance of zomepirac by 64%, which resulted in an increase in bioavailability from 0.55 without probenecid to 0.84 when given concurrently.",Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3874742/),,0.84,81794,DB00500,Tolmetin
,3874742,ratio of the total clearance/bioavailability,"The ratio of the total clearance/bioavailability of zomepirac in control subjects was 682 +/- 246 ml/min, which is double the value reported in previous studies of zomepirac disposition.",Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3874742/),[ml] / [min],682,81795,DB00500,Tolmetin
,1458761,Cmax,"The absorption of ketorolac is rapid, Cmax being attained between 20 to 60 min.",Clinical pharmacokinetics of ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),min,20 to 60,102714,DB00500,Tolmetin
,1458761,oral bioavailability,Its oral bioavailability is estimated to range from 80 to 100%.,Clinical pharmacokinetics of ketorolac tromethamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),%,80 to 100,102715,DB00500,Tolmetin
,1458761,volume of distribution,The drug is extensively bound (> 99%) to plasma proteins and has a volume of distribution (0.1 to 0.3 L/kg) comparable with those of other NSAIDs.,Clinical pharmacokinetics of ketorolac tromethamine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),[l] / [kg],0.1 to 0.3,102716,DB00500,Tolmetin
,1458761,elimination half-life,The elimination half-life is between 4 and 6h and is moderate in comparison with other NSAIDs.,Clinical pharmacokinetics of ketorolac tromethamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),h,4 and 6,102717,DB00500,Tolmetin
,445955,peak time,"Tolmetin was rapidly and completely absorbed (peak time, 20 to 60 min) and eliminated rapidly from plasma with a biphasic decay curve (t1/2beta congruent to 2.1 hr).",Absorption and excretion of tolmetin in arthritic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445955/),min,20 to 60,104002,DB00500,Tolmetin
,445955,t1/2beta,"Tolmetin was rapidly and completely absorbed (peak time, 20 to 60 min) and eliminated rapidly from plasma with a biphasic decay curve (t1/2beta congruent to 2.1 hr).",Absorption and excretion of tolmetin in arthritic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445955/),h,2.1,104003,DB00500,Tolmetin
,445955,peak time,"MCPA, the oxidative metabolite, appeared more slowly (peak time, 40 to 90 min) but was eliminated rapidly in a biphasic manner (t1/2beta congruent to 1.7 hr).",Absorption and excretion of tolmetin in arthritic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445955/),min,40 to 90,104004,DB00500,Tolmetin
,445955,t1/2beta,"MCPA, the oxidative metabolite, appeared more slowly (peak time, 40 to 90 min) but was eliminated rapidly in a biphasic manner (t1/2beta congruent to 1.7 hr).",Absorption and excretion of tolmetin in arthritic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445955/),h,1.7,104005,DB00500,Tolmetin
,9187531,maximum daily dosage,"The maximum daily dosage is 90mg, and the maximum duration of treatment is 48 hours.",Ketorolac for postoperative pain management in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9187531/),,90,112027,DB00500,Tolmetin
greater,8135994,bioavailability,Ketorolac applied in this way had a bioavailability greater than 80%.,Nasal formulations of ketorolac tromethamine: technological evaluation--bioavailability and tolerability in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135994/),%,80,132170,DB00500,Tolmetin
,2303585,half-life,"The elimination of ketorolac was decreased slightly in the elderly following both doses, as evidenced by a prolongation in half-life (4.7 to 6.1 hours for PO and 4.5 to 7.0 hours for IM) and a reduced total plasma clearance compared to the young adult subjects.",Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303585/),h,4.7 to 6.1,141658,DB00500,Tolmetin
,2303585,half-life,"The elimination of ketorolac was decreased slightly in the elderly following both doses, as evidenced by a prolongation in half-life (4.7 to 6.1 hours for PO and 4.5 to 7.0 hours for IM) and a reduced total plasma clearance compared to the young adult subjects.",Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303585/),h,4.5 to 7.0,141659,DB00500,Tolmetin
,7952121,run time,Detection was at 325 nm and run time was 10 min.,Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,10,142547,DB00500,Tolmetin
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,3.3,142548,DB00500,Tolmetin
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,4.8,142549,DB00500,Tolmetin
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,6.4,142550,DB00500,Tolmetin
,7952121,retention time,The metabolite p-hydroxyketorolac was not resolved enantiomerically and had a retention time of 2.2 min.,Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,2.2,142551,DB00500,Tolmetin
,20853464,flow rate,"Chromatographic separation was achieved with 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 0.50 mL/min on an X-Terra RP(18) column with a total run time of 2.5 min.","Validation and clinical application of an LC-ESI-MS/MS method for simultaneous determination of tolmetin and MED5, the metabolites of amtolmetin guacil in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853464/),[ml] / [min],0.50,149836,DB00500,Tolmetin
,20853464,total run time,"Chromatographic separation was achieved with 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 0.50 mL/min on an X-Terra RP(18) column with a total run time of 2.5 min.","Validation and clinical application of an LC-ESI-MS/MS method for simultaneous determination of tolmetin and MED5, the metabolites of amtolmetin guacil in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853464/),min,2.5,149837,DB00500,Tolmetin
,3783453,half-life,"Haloperidol (4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1- butanone), a reference compound used for model development, disappeared from the intestinal lumen with a half-life of 14 +/- 3 min.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),min,14,155304,DB00500,Tolmetin
,3783453,t1/2,"When the antiarthritic agent, tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetate dihydrate), was studied in the preparation, it was rapidly absorbed (t1/2 for disappearance from the intestinal lumen = 8 min), achieved plasma concentrations comparable to in vivo data, and underwent little presystemic elimination.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),min,8,155305,DB00500,Tolmetin
,3783453,t1/2,"In contrast, fenoctimine sulfate (4-(diphenylmethyl)-1-[(octylimino)methyl]piperidine sulfate), an antisecretory compound, disappeared more slowly from the intestinal lumen (t1/2 = 60 min), was present in portal plasma, but was not detected in systemic plasma.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),min,60,155306,DB00500,Tolmetin
,3783453,t1/2,"Tolmetin glycine amide (N-([1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl)glycine), a tolmetin prodrug, disappeared from the intestinal lumen very slowly (t1/2 approximately 3 h) compared with the other agents tested.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),h,3,155307,DB00500,Tolmetin
,2082311,half-life for absorption,It is absorbed rapidly (half-life for absorption 3.8 min) after oral (fasting) and intramuscular administration; food delays but does not reduce its absorption.,"Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),min,3.8,162671,DB00500,Tolmetin
,2082311,plasma elimination half-life,"The mean plasma elimination half-life is 5-6 hours, and ketorolac is not extensively distributed outside the vascular compartment (Vd beta 15 L).","Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),h,5-6,162672,DB00500,Tolmetin
,2082311,Vd beta,"The mean plasma elimination half-life is 5-6 hours, and ketorolac is not extensively distributed outside the vascular compartment (Vd beta 15 L).","Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),l,15,162673,DB00500,Tolmetin
,897347,apparent elimination half-life,The apparent elimination half-life of tolmetin is shown to be 4.5 to 6.0 hours.,Linear and nonlinear assessment of tolmetin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/897347/),h,4.5 to 6.0,170228,DB00500,Tolmetin
,8903001,EC50),"Using the sigmoidal Emax model the mean serum concentration (SD) of ketorolac, 4-methylaminoantipyrine and 4-aminoantipyrine inhibiting platelet TXB2 generation by 50% (EC50) in vitro was found to be 0.088 +/- 0.031, 1.2 +/- 0.3 and 10.2 +/- 3.4 micrograms ml-1, respectively.",The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903001/),[μg] / [ml],0.088,171050,DB00500,Tolmetin
,8903001,EC50),"Using the sigmoidal Emax model the mean serum concentration (SD) of ketorolac, 4-methylaminoantipyrine and 4-aminoantipyrine inhibiting platelet TXB2 generation by 50% (EC50) in vitro was found to be 0.088 +/- 0.031, 1.2 +/- 0.3 and 10.2 +/- 3.4 micrograms ml-1, respectively.",The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903001/),[μg] / [ml],1.2,171051,DB00500,Tolmetin
,8903001,EC50),"Using the sigmoidal Emax model the mean serum concentration (SD) of ketorolac, 4-methylaminoantipyrine and 4-aminoantipyrine inhibiting platelet TXB2 generation by 50% (EC50) in vitro was found to be 0.088 +/- 0.031, 1.2 +/- 0.3 and 10.2 +/- 3.4 micrograms ml-1, respectively.",The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903001/),[μg] / [ml],10.2,171052,DB00500,Tolmetin
,8863274,dose-corrected systemic availability,The dose-corrected systemic availability of the three oral rinses evaluated in the rinse study relative to the peroral capsule was about 15%.,Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,15,172454,DB00500,Tolmetin
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,59.2,172455,DB00500,Tolmetin
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,86.4,172456,DB00500,Tolmetin
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,1.0,172457,DB00500,Tolmetin
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,0.15,172458,DB00500,Tolmetin
,8863274,relative bioavailabilities,The relative bioavailabilities of ketorolac in the GCF after dosing with the dentifrice formulations with respect to the rinse were 89.1% for the 1.0% dentifrice and 19.7% for the 0.15% dentifrice.,Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,89.1,172459,DB00500,Tolmetin
,8863274,relative bioavailabilities,The relative bioavailabilities of ketorolac in the GCF after dosing with the dentifrice formulations with respect to the rinse were 89.1% for the 1.0% dentifrice and 19.7% for the 0.15% dentifrice.,Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,19.7,172460,DB00500,Tolmetin
,8863274,T1/2,"The T1/2 of ketorolac in the GCF was about 0.5 h for all three treatments, which is significantly less than the plasma half-life of about 5.3 h.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),h,0.5,172461,DB00500,Tolmetin
,8863274,plasma half-life,"The T1/2 of ketorolac in the GCF was about 0.5 h for all three treatments, which is significantly less than the plasma half-life of about 5.3 h.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),h,5.3,172462,DB00500,Tolmetin
,1820937,bioavailability,Oral paracetamol bioavailability reduction (24%) was observed by coadministration of tolmetin in the rat.,Reduction of oral bioavailability of paracetamol by tolmetin in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820937/),%,24,173344,DB00500,Tolmetin
,1418060,K01,"After oral administration, the drug was absorbed rapidly (K01 = 0.1304 min-1).",Pharmacokinetic study of tolmetin in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418060/),1/[min],0.1304,187537,DB00500,Tolmetin
,1418060,bioavailability,"The bioavailability was 96.94% and the drug was mostly excreted as 1-methyl-5-(4-carboxybenzoyl)-1H-pyrrole-2-acetic acid, while the excretion of the unchanged drug was 6.12%.",Pharmacokinetic study of tolmetin in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418060/),%,96.94,187538,DB00500,Tolmetin
,1418060,excretion,"The bioavailability was 96.94% and the drug was mostly excreted as 1-methyl-5-(4-carboxybenzoyl)-1H-pyrrole-2-acetic acid, while the excretion of the unchanged drug was 6.12%.",Pharmacokinetic study of tolmetin in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418060/),%,6.12,187539,DB00500,Tolmetin
,7357796,absorption rate constant (Ka),"Plasma concentration profile could be described by the 2-compartmentoral absorption model with an absorption rate constant (Ka) of 7.66 hr-1 t 1/2 = 0.09 hr), a rapid disposition rate constant (alpha) of 0.75 hr-1 (t 1/2 = 0.94 hr), and a slow disposition rate constant (beta) of 0.16 hr-1 (t 1/2 = 4.3 hr).",Zomepirac kinetics in healthy males. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357796/),hr-,7.66,192320,DB00500,Tolmetin
,7357796,t 1/2,"Plasma concentration profile could be described by the 2-compartmentoral absorption model with an absorption rate constant (Ka) of 7.66 hr-1 t 1/2 = 0.09 hr), a rapid disposition rate constant (alpha) of 0.75 hr-1 (t 1/2 = 0.94 hr), and a slow disposition rate constant (beta) of 0.16 hr-1 (t 1/2 = 4.3 hr).",Zomepirac kinetics in healthy males. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357796/),h,0.09,192321,DB00500,Tolmetin
,7357796,disposition rate constant (alpha),"Plasma concentration profile could be described by the 2-compartmentoral absorption model with an absorption rate constant (Ka) of 7.66 hr-1 t 1/2 = 0.09 hr), a rapid disposition rate constant (alpha) of 0.75 hr-1 (t 1/2 = 0.94 hr), and a slow disposition rate constant (beta) of 0.16 hr-1 (t 1/2 = 4.3 hr).",Zomepirac kinetics in healthy males. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357796/),1/[h],0.75,192322,DB00500,Tolmetin
,7357796,t 1/2,"Plasma concentration profile could be described by the 2-compartmentoral absorption model with an absorption rate constant (Ka) of 7.66 hr-1 t 1/2 = 0.09 hr), a rapid disposition rate constant (alpha) of 0.75 hr-1 (t 1/2 = 0.94 hr), and a slow disposition rate constant (beta) of 0.16 hr-1 (t 1/2 = 4.3 hr).",Zomepirac kinetics in healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357796/),h,0.94,192323,DB00500,Tolmetin
,7357796,disposition rate constant (beta),"Plasma concentration profile could be described by the 2-compartmentoral absorption model with an absorption rate constant (Ka) of 7.66 hr-1 t 1/2 = 0.09 hr), a rapid disposition rate constant (alpha) of 0.75 hr-1 (t 1/2 = 0.94 hr), and a slow disposition rate constant (beta) of 0.16 hr-1 (t 1/2 = 4.3 hr).",Zomepirac kinetics in healthy males. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357796/),1/[h],0.16,192324,DB00500,Tolmetin
,7357796,t 1/2,"Plasma concentration profile could be described by the 2-compartmentoral absorption model with an absorption rate constant (Ka) of 7.66 hr-1 t 1/2 = 0.09 hr), a rapid disposition rate constant (alpha) of 0.75 hr-1 (t 1/2 = 0.94 hr), and a slow disposition rate constant (beta) of 0.16 hr-1 (t 1/2 = 4.3 hr).",Zomepirac kinetics in healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357796/),h,4.3,192325,DB00500,Tolmetin
,6107233,F,"Assessment of Z's absolute bioavailability in monkeys (10 mg/kg, iv vs. po) indicated that po doses of ZS were completely bioavailable (F = 1.12 +/- 0.40).",The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107233/),,1.12,197744,DB00500,Tolmetin
,6107233,Plasma clearance,"Plasma clearance ranged from ca. 4.5 ml/min/kg for the female hamster, rhesus monkey, and man to as low as 0.30 ml/min/kg for rats, mice, and rabbits.",The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107233/),[ml] / [kg·min],4.5,197745,DB00500,Tolmetin
,6107233,Plasma clearance,"Plasma clearance ranged from ca. 4.5 ml/min/kg for the female hamster, rhesus monkey, and man to as low as 0.30 ml/min/kg for rats, mice, and rabbits.",The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107233/),[ml] / [kg·min],0.30,197746,DB00500,Tolmetin
,6107233,Terminal elimination half-lives,"Terminal elimination half-lives averaged 5.3--6.6 hr for mouse, 2.8--6.5 hr for rat, 2.5 hr for rabbit, 2.3 hr for hamster, 12.7--25.5 hr for rhesus monkey, and 4 hr for man.",The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107233/),h,5.3,197747,DB00500,Tolmetin
,6107233,Terminal elimination half-lives,"Terminal elimination half-lives averaged 5.3--6.6 hr for mouse, 2.8--6.5 hr for rat, 2.5 hr for rabbit, 2.3 hr for hamster, 12.7--25.5 hr for rhesus monkey, and 4 hr for man.",The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107233/),h,2.8,197748,DB00500,Tolmetin
,6107233,Terminal elimination half-lives,"Terminal elimination half-lives averaged 5.3--6.6 hr for mouse, 2.8--6.5 hr for rat, 2.5 hr for rabbit, 2.3 hr for hamster, 12.7--25.5 hr for rhesus monkey, and 4 hr for man.",The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107233/),h,2.5,197749,DB00500,Tolmetin
,6107233,Terminal elimination half-lives,"Terminal elimination half-lives averaged 5.3--6.6 hr for mouse, 2.8--6.5 hr for rat, 2.5 hr for rabbit, 2.3 hr for hamster, 12.7--25.5 hr for rhesus monkey, and 4 hr for man.",The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107233/),h,2.3,197750,DB00500,Tolmetin
,6107233,Terminal elimination half-lives,"Terminal elimination half-lives averaged 5.3--6.6 hr for mouse, 2.8--6.5 hr for rat, 2.5 hr for rabbit, 2.3 hr for hamster, 12.7--25.5 hr for rhesus monkey, and 4 hr for man.",The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107233/),h,12.7,197751,DB00500,Tolmetin
,6107233,Terminal elimination half-lives,"Terminal elimination half-lives averaged 5.3--6.6 hr for mouse, 2.8--6.5 hr for rat, 2.5 hr for rabbit, 2.3 hr for hamster, 12.7--25.5 hr for rhesus monkey, and 4 hr for man.",The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107233/),h,4,197752,DB00500,Tolmetin
,2787750,maximum potential amount,"The maximum potential amount of ketorolac that an infant may be exposed to daily could range from 3.16 mg to 7.9 mg, assuming a consumption of between 400 ml and 1 l of breast milk.",The excretion of ketorolac tromethamine into breast milk after multiple oral dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2787750/),,3,200410,DB00500,Tolmetin
,8988064,drug concentration at half-maximal effect (EC50),The drug concentration at half-maximal effect (EC50) and the first-order rate constant (keo) half-life for pain relief were 0.37 mg/L and 24 minutes.,Population pharmacodynamic model for ketorolac analgesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988064/),[mg] / [l],0.37,203579,DB00500,Tolmetin
,8988064,first-order rate constant (keo) half-life,The drug concentration at half-maximal effect (EC50) and the first-order rate constant (keo) half-life for pain relief were 0.37 mg/L and 24 minutes.,Population pharmacodynamic model for ketorolac analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988064/),min,24,203580,DB00500,Tolmetin
,1126116,plasma half-life,"For the 12 subjects studied, the overall mean elimination rate constant was 0.839 hr-1, corresponding to a plasma half-life of 0.83 hr.",Pharmacokinetic studies of tolmetin in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1126116/),h,0.83,226842,DB00500,Tolmetin
,1126116,apparent volume of distribution,The drug was rapidly absorbed and had a mean apparent volume of distribution of 0.098 l/kg.,Pharmacokinetic studies of tolmetin in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1126116/),[l] / [kg],0.098,226843,DB00500,Tolmetin
,7848629,Detection limit,Detection limit of the method was 3 ng/ml using 1 ml of plasma and 10 ng/ml using 0.2 ml of blood.,Determination of ketorolac in blood and plasma samples by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848629/),[ng] / [ml],3,232476,DB00500,Tolmetin
,7848629,Detection limit,Detection limit of the method was 3 ng/ml using 1 ml of plasma and 10 ng/ml using 0.2 ml of blood.,Determination of ketorolac in blood and plasma samples by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848629/),[ng] / [ml],10,232477,DB00500,Tolmetin
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],180,234456,DB00500,Tolmetin
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],177,234457,DB00500,Tolmetin
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],14,234458,DB00500,Tolmetin
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],1.265,234459,DB00500,Tolmetin
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],0.696,234460,DB00500,Tolmetin
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],0.092,234461,DB00500,Tolmetin
,7299689,plasma clearance,"After the 40 mg/kg dose, about 2.5-fold higher peak zomepirac plasma concentrations and area under the curve were observed that predicted from the lower doses and plasma clearance decreased from 4.6 to 1.8 ml/min/kg.",Dose-dependent pharmacokinetics and renal handling of zomepirac in rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299689/),[ml] / [kg·min],4.6,241637,DB00500,Tolmetin
,7299689,plasma clearance,"After the 40 mg/kg dose, about 2.5-fold higher peak zomepirac plasma concentrations and area under the curve were observed that predicted from the lower doses and plasma clearance decreased from 4.6 to 1.8 ml/min/kg.",Dose-dependent pharmacokinetics and renal handling of zomepirac in rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299689/),[ml] / [kg·min],1.8,241638,DB00500,Tolmetin
,7299689,Renal clearance,Renal clearance of zomepirac averted only 0.007 ml/min/kg and was concentration independent.,Dose-dependent pharmacokinetics and renal handling of zomepirac in rhesus monkeys. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299689/),[ml] / [kg·min],0.007,241639,DB00500,Tolmetin
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.24,241866,DB00500,Tolmetin
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0. 29,241867,DB00500,Tolmetin
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.08,241868,DB00500,Tolmetin
less,2891477,Tmax,KT was absorbed rapidly (Tmax less than 1.0 hr) and efficiently (greater than 87%) following po and im doses in all species.,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),h,1.0,247960,DB00500,Tolmetin
,2891477,plasma half-life,The plasma half-life of ketorolac (K) ranged from 1.1 hr (rabbits) to 6.0 hr (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),h,1.1,247961,DB00500,Tolmetin
,2891477,plasma half-life,The plasma half-life of ketorolac (K) ranged from 1.1 hr (rabbits) to 6.0 hr (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),h,6.0,247962,DB00500,Tolmetin
,2891477,protein binding,The protein binding of K ranged from 72.0% (mouse) to 99.2% (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),%,72.0,247963,DB00500,Tolmetin
,2891477,protein binding,The protein binding of K ranged from 72.0% (mouse) to 99.2% (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),%,99.2,247964,DB00500,Tolmetin
,2275236,apparent volume of distribution,Ketorolac is more than 99 percent bound to plasma proteins and has a mean apparent volume of distribution of 0.11-0.25 L/kg.,Ketorolac: a parenteral nonsteroidal antiinflammatory drug. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2275236/),[l] / [kg],0.11-0.25,255157,DB00500,Tolmetin
,35605,plasma elimination half-life,Adjustment of urine pH to the alkaline range caused more than an 8-fold lowering of the plasma elimination half-life (from 7.0 to 0.8 hr) and enhanced renal clearance by a factor of 53 compared to control.,Renal handling of zomepirac sodium (McN-2783-21-98) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/35605/),h,7.0,258161,DB00500,Tolmetin
,35605,plasma elimination half-life,Adjustment of urine pH to the alkaline range caused more than an 8-fold lowering of the plasma elimination half-life (from 7.0 to 0.8 hr) and enhanced renal clearance by a factor of 53 compared to control.,Renal handling of zomepirac sodium (McN-2783-21-98) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/35605/),h,0.8,258162,DB00500,Tolmetin
,35605,elimination half-life,"Acidification of the urine or probenecid administration increased the elimination half-life (to 10.9 and 17.5 hr, respectively), and decreased renal and plasma clearance of zomepirac.",Renal handling of zomepirac sodium (McN-2783-21-98) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/35605/),h,10.9,258163,DB00500,Tolmetin
,35605,elimination half-life,"Acidification of the urine or probenecid administration increased the elimination half-life (to 10.9 and 17.5 hr, respectively), and decreased renal and plasma clearance of zomepirac.",Renal handling of zomepirac sodium (McN-2783-21-98) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/35605/),h,17.5,258164,DB00500,Tolmetin
